The United Kingdom and the United States have finalized a landmark bilateral deal that will ensure no levies on British medicine exports entering the American market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has pledged to increase spending on medicines through the NHS. This pledge guarantees that import taxes on these key exports will remain at nothing for a duration of 36 months.
This agreement is in response to recent threats to hike duties on patented pharmaceutical imports, with figures mentioned reaching 100%.
"This agreement between the United Kingdom reinforces the worldwide climate for cutting-edge drugs and brings much-needed equity to American-British drug exports," a release said.
Economic Impact
Drugs represent one of the Britain's biggest goods shipped to the United States, which is easily the largest buyer for leading companies like GSK and AstraZeneca.
Trade data reveal that in the 12 months prior to last September, the UK exported drugs worth over eleven billion pounds to the US. This value made up nearly one-fifth of all goods exports in that span.
"This guarantee secures employment, stimulates investment and paves the way for the UK to establish itself as a global hub for life sciences," the Business and Trade Secretary stated.
Key British Pledges
The deal involves several key commitments from the British government:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it deems new medicines to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a goal to increase overall NHS spending on medicines from 0.3% of GDP to 0.6% over the next decade.
- Rebate Cap: The percentage manufacturers must refund to the NHS to control costs will be restricted at fifteen percent. Last year, repayments topped 20%.
Industry Background
The deal follows a protracted dispute between the drug companies and the UK government over drug pricing and NHS adoption.
These tensions were intensified by claims that American consumers were paying significantly more for the equivalent treatments than people in the Britain and the EU.
Recently, several large pharmaceutical investments in the UK have been delayed or abandoned, while multi-billion-dollar investments have been directed toward American operations.
A senior figure acknowledged that the NHS had to increase expenditure on treatments, noting that its spending on drugs had shrunk as a percentage of its total funding over the previous ten-year period.
